Talks with major global pharmaceutical companies for OSCA and organoid collaboration
[by Kang, In Hyo] 메이저 바카라사이트 장난감 Biotech announced on January 5 that it has received an official invitation to participate in the J.P. Morgan Healthcare Conference 2026, scheduled to be held in San Francisco from January 12 to 15 (local time).
The J.P. Morgan Healthcare Conference is widely recognized as the world's largest biotechnology and healthcare investment conference, bringing together top executives from leading global pharmaceutical and biotechnology companies, international investors, regulatory authorities, and major media organizations. Participation is extended to only a select group of companies each year. Kangstem Biotech stated that this invitation reflects global recognition of the commercial potential and technological competitiveness of its core pipeline asset, ‘OSCA,’ a treatment candidate for knee osteoarthritis, as well as its proprietary skin and hair follicle organoid platform.
메이저 바카라사이트 장난감 Biotech has conducted scientific validation of its OSCA program and organoid-based technology in collaboration with multiple multinational pharmaceutical companies. During the conference, the company plans to engage in in-depth discussions covering collaboration terms, development scope, and schedules. Through this, 메이저 바카라사이트 장난감 Biotech aims to advance ongoing negotiations and concretize a partnership framework with strong commercial potential.
In particular, multinational pharmaceutical companies are increasingly exploring the adoption of skin and hair follicle organoid platforms as a means of improving efficiency and predictive accuracy in preclinical research. In response, 메이저 바카라사이트 장난감 Biotech plans to refine discussions on a co-development framework, including division of roles and responsibilities, centered on a dedicated collaborative team comprising development specialists and business development (BD) professionals from partner organizations.
"The midterm clinical advancement of OSCA and our skin and hair follicle organoid platforms has been recognized by global partners as 'must-have technologies.' In the osteoarthritis treatment field, where fundamental treatments remain limited, OSCA has the potential to emerge as a global blockbuster candidate, supported by its differentiated safety profile and clinical progress," a Kangstem Biotech official stated.
Conversely, 메이저 바카라사이트 장난감 Biotech completed patient dosing in a Phase 2a clinical trial of OSCA, its knee osteoarthritis treatment candidate, in November 2025 and plans to disclose top-line data around July of this year. The company's near-term strategy is to enhance global partnering visibility through its participation in the JP Morgan Healthcare Conference, while pursuing technology transfer agreements and co-development initiatives over the mid- to long-term, with the objective of strengthening overall corporate value.